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endolysosomal system in vivo
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Abstract
The most common mutation in the Leucine-rich repeat kinase 2 gene (LRRK2), G2019S, causes familial Parkinson’s
Disease (PD) and renders the encoded protein kinase hyperactive. While targeting LRRK2 activity is currently being
tested in clinical trials as a therapeutic avenue for PD, to date, the molecular effects of chronic LRRK2 inhibition
have not yet been examined in vivo. We evaluated the utility of newly available phospho-antibodies for Rab
substrates and LRRK2 autophosphorylation to examine the pharmacodynamic response to treatment with the
potent and specific LRRK2 inhibitor, MLi-2, in brain and peripheral tissue in G2019S LRRK2 knock-in mice. We report
higher sensitivity of LRRK2 autophosphorylation to MLi-2 treatment and slower recovery in washout conditions
compared to Rab GTPases phosphorylation, and we identify pS106 Rab12 as a robust readout of downstream
LRRK2 activity across tissues. The downstream effects of long-term chronic LRRK2 inhibition in vivo were evaluated
in G2019S LRRK2 knock-in mice by phospho- and total proteomic analyses following an in-diet administration of
MLi-2 for 10 weeks. We observed significant alterations in endolysosomal and trafficking pathways in the kidney
that were sensitive to MLi-2 treatment and were validated biochemically. Furthermore, a subtle but distinct
biochemical signature affecting mitochondrial proteins was observed in brain tissue in the same animals that, again,
was reverted by kinase inhibition. Proteomic analysis in the lung did not detect any major pathway of dysregulation
that would be indicative of pulmonary impairment. This is the first study to examine the molecular underpinnings
of chronic LRRK2 inhibition in a preclinical in vivo PD model and highlights cellular processes that may be
influenced by therapeutic strategies aimed at restoring LRRK2 physiological activity in PD patients.
Background
Mutations in leucine-rich repeat kinase 2 (LRRK2) are a
known genetic cause of familial Parkinson’s disease (PD)
[1–3];. Non-coding variation at the LRRK2 locus has also
been identified as a risk factor for sporadic PD, suggest-
ing that both disease forms share common pathological
mechanisms [4, 5]. The G2019S mutation, which lies
within the kinase domain of LRRK2, is the most com-
mon mutation found in familial PD cases, as well as in
1–5% of apparently sporadic PD patients [6]. This muta-
tion directly increases kinase activity while other muta-
tions likely have convergent cellular effects, albeit
through varying mechanisms [4]. Therefore, it is thought
that targeting LRRK2 therapeutically may be advanta-
geous in both familial and sporadic PD [7, 8].
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A number of pharmacological tools that inhibit LRRK2
kinase activity in the CNS have been developed and
characterized [9]. Some kinase inhibitors have been
shown to reduce cytotoxicity associated with LRRK2
mutations in PD-relevant cell and animal models [10–
12], supporting the hypothesis that LRRK2 inhibition
may be efficacious for PD. One such LRRK2-specific in-
hibitor, MLi-2, has been found to be ~300x more select-
ive for LRRK2 over other kinases and can readily cross
the blood-brain barrier [13] demonstrating that it is pos-
sible to generate tool compounds that have clinical po-
tential for therapeutic intervention in PD. However, as
LRRK2 is expressed endogenously in many tissues and
kinase inhibition is predicted to affect both mutant and
wild-type LRRK2, whether such inhibitors would be safe
to use clinically is uncertain. Preclinical studies have re-
ported macroscopic changes in vivo that include mor-
phological changes in lung from nonhuman primates,
and kidney tissue from rats treated with specific LRRK2
inhibitors that are reversible after termination of treat-
ment [14–16]. Importantly, some of these effects overlap
with those seen in Lrrk2 knockout mice [17] demon-
strating that they result from on-target effects of inhibi-
tors on LRRK2 itself rather than resulting from
inhibition of other kinases.
Here, we aimed to mimic a likely clinical use of
LRRK2 inhibitor to understand the relationship between
level of inhibition and effects on biochemistry of target
tissues including brain and peripheral organs that ex-
press high levels of LRRK2. We first evaluated the utility
of measuring autophosphorylation of LRRK2 vs down-
stream substrate Rab proteins as readouts of LRRK2 kin-
ase activity in vivo across a series of acute and chronic
dosing paradigms in kinase hyperactive G2019S LRRK2
knock-in mouse model. Secondly, we explore the mo-
lecular effects of long-term chronic LRRK2 inhibition by
unbiased total and phospho-proteomics on brain, kidney,
and lung tissue from G2019S LRRK2 mice following 60
mg/kg/day in-diet dosing of MLi-2 for 10 weeks. Based
on these data, we report molecular pathways that are af-
fected by chronic inhibition of LRRK2 in a clinically
relevant paradigm. Importantly, we show that the effects
of LRRK2 inhibition vary across tissues, which may be
particularly relevant to selection of biomarkers for clin-




All animal procedures were performed in accordance
with a protocol approved by the Institutional Animal
Care and Use Committee of the National Institute on
Aging, NIH.
Wildtype, G2019S LRRK2 knock-in (KI), and LRRK2
knockout (KO) male and female mice raised on a C57Bl/
6 background (3–8 months in age) were bred in-house
on a 12-h day/night cycle for the following experiments.
All mice were supplied with Rodent NIH-07 diet and
water ad libitum.
Acute MLi-2 dosing
Dose response: 28 homozygous G2019S KI C57BL/6 J
mice (5–8 months old) were randomized for treatment
using the sample function in R, followed by matching
for sex across groups. Mice were given an acute dose of
vehicle [40% (w/v) Hydroxypropyl-β-Cyclodextran] or
MLi-2 (at 1, 3, 10, 30, 60, or 90 mg/kg dissolved in ve-
hicle) via oral gavage and euthanized 1 h after treatment.
Based on our previous data on S1292 dephosphorylation
in G2019S LRRK2 brain following acute MLi-2 treat-
ment [18], N = 4 was used in this study for all acute
MLi-2 experiments, as it was estimated at 90% power to
detect a difference of effect size 6 at alpha = 0.05.
Time course: 28 homozygous G2019S KI C57BL/6 J
mice (4–7 months old) were randomized for treatment
using the sample function in R, followed by matching
for sex across groups. Mice were given an acute dose of
vehicle [40% (w/v) Hydroxypropyl-β-Cyclodextran] at
time point zero, or MLi-2 (10 mg/kg dissolved in ve-
hicle) via oral gavage and euthanized after time point
0.5, 1, 3, 12, 24, or 72 h post dose.
Chronic in-diet dosing
To determine the appropriate concentration of MLi-2
necessary to achieve S1292 phosphorylation levels that
are comparable to the brain tissue levels in a wildtype
animal, homozygous G2019S KI mice were given cus-
tomized Rodent NIH-07 chow from Research Diets, ei-
ther untreated or supplemented with various doses of
MLi-2 (10, 30, or 60 mg/kg/day) for 10 days along with
an untreated wildtype group, and S1292 phosphorylation
signal was measured via Western blot (N = 3 mice were
used per treatment group). Mice and chow were
weighed daily to assess estimated doses of MLi-2 re-
ceived each day. No difference was observed in food in-
take between mice receiving MLi-2 treated chow and
mice receiving untreated chow. All mice were given
chow and water ad libitum. After 10 days, mice were eu-
thanized 2-3 h post start of their light cycle.
Ten day (short-term) and 10 week (long-term) chronic
cohorts: Three-month old littermates from wildtype,
homozygous G2019S KI, and homozygous LRRK2 KO
litters were randomized into short-term (10 days) and
long-term (10 weeks) chronic treatment groups: wild-
type, G2019S KI, and LRRK2 KO groups received un-
treated chow, and a G2019S KI group received chow
supplemented with 60mg/kg of MLi-2 per day. Both
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male and female mice were represented equally in all
treatment groups (N = 6 mice were used per treatment
group). All mice were given chow and water ad libitum.
After 10 days, or 10 weeks, mice were euthanized 2-3 h
post start of their light cycle.
Statistical analyses
Statistical analyses for each experiment can be found
within each respective figure legend. Briefly, one-way
ANOVA or two-way ANOVA with Tukey’s post hoc-
test were used which were performed in GraphPad
Prism v8.2.0 (GraphPad Software, San Diego, CA). If not
otherwise stated, comparisons were considered statisti-
cally significant where p < 0.05. *, p < 0.05; **, p < 0.01;
***, p < 0.001; ****, p < 0.0001.
Immunoblotting
Tissues were homogenized at 20% w/v in 1x Cell Signal-
ing Lysis Buffer (#9803S) with 1x protease and phos-
phatase inhibitors (Thermofisher; #1861279 and #78427,
respectively) and left on ice for 30 min to lyse. Homoge-
nates were spun at 20,000 g for 10 min at 4 degrees Cel-
sius and pelleted debris were removed. Samples were
supplemented with NuPage LDS sample buffer 4x
(#NP0008), boiled for 5 min at 95 degrees Celsius and
run on a Bio-Rad Criterion™ TGX™ polyacrylamide gel
(#5671095) at 200 V for 37 min. Gels were transferred to
nitrocellulose (#1704159) on a Bio-Rad Trans-Blot
Turbo™ transfer system at 20 V for 10 min. A normalizer
sample was added to the end of each blot to account for
day-to-day variability in protein transfer and antibody
incubation. This stock was prepared prior to beginning
this study and single-use aliquots were prepared in load-
ing buffer and stored at -80C until use to ensure no loss
of phosphorylation nor protein degradation. The nitro-
cellulose was blocked for 1 h in 50% TBS (20 mM Tris,
0.5M NaCl, pH 7.5), 50% Odyssey blocking buffer (Li-
Cor; 927–40,000) and incubated overnight with primary
antibodies in 50% TBS-T (20 mM Tris, 0.5M NaCl, pH
7.5, 0.1% Tween 20), 50% Odyssey blocking buffer at 4
degrees Celsius. All antibody concentrations used in this
study can be found in Table S1. Following 3 × 5min
washes with TBS-T, the nitrocellulose was incubated at
RT with secondary antibodies for 1 h, washed 3 × 5min
and scanned at the Li-Cor platform.
All primary antibodies and working dilutions can be
found in Table S1. Secondary antibodies were used at 1:
10,000 dilution: IRDyes 800CW Goat anti-Rabbit IgG
(LiCor; #926–32,211) and 680RD Goat anti-Mouse IgG
(LiCor; 926–68,070). All blots presented in each figure
panel were derived from the same experiment and were
processed in parallel. Raw densitometric signal was nor-
malized to a common normalizer sample that was run
on every blot.
Tissue preparation for proteomics and
phosphoproteomics
One brain hemisphere, one half of a kidney, and one
whole lung from each mouse in the short-term and
long-term chronic experiments were processed and sub-
mitted for proteomics and phosphoproteomics analysis
using TMT quantitation without and with TiO2/iMAC
enrichment. Briefly, tissues were homogenized in 15%
w/v lysis buffer (0.5 mM HEPES, pH 7.4, 225 mM man-
nitol, 50 mM sucrose, 1 mM EDTA, 1x protease and
phosphatase inhibitors (Thermofisher; #1861279 and
#78427, respectively), and 2% CHAPS) followed by incu-
bation on ice for 30 min, with periodic vortexing, to lyse.
The homogenates were then spun down at 20,000 g at 4
degrees Celsius for 10 min to pellet cellular debris. A
protein assay was performed on supernatants to deter-
mine protein concentration, and 270 μg of each sample
were submitted for mass spectrometry. Additionally,
30 μg of each sample were pooled together to allow for
normalization between runs during analysis.
Phosphoproteomics and bioinformatics analysis
Proteins were alkylated with NEM, digested with trypsin
and labeled with TMTpro reagents. The brain and kid-
ney samples were treated with the same method. Forty
eight brain/kidney samples and 4 pooled samples were
separated into 4 sets of TMT experiments. Each set con-
tains 12 samples and one pooled sample. Twenty-four
whole lung samples and 2 pooled samples were sepa-
rated into 2 sets of TMT experiments. Each set contains
12 samples and one pooled sample. The pooled sample
in each set was labeled with TMTpro-126 reagent, while
the distribution and labeling of 12 samples were ran-
domized (Data File S1). After the labeling and quench-
ing, samples were combined together. 95% of the
combined sample was used for phosphopeptide enrich-
ment using TiO2 method followed by iMAC method.
5% of the combined sample was fractionated using
Pierce high pH reverse phase cartridge, and 8 fractions
were collected for each set. LC-MS/MS data acquisition
were performed on a Thermo Scientific Orbitrap Lumos
mass spectrometer which was coupled to a Thermo Sci-
entific Ultimate 3000 HPLC. Peptides were separated on
an ES802 nano-column over 136 min at a flow rate of
300 n/min. TMT MS2 method was used. Both MS1 and
MS2 scans were performed in orbitrap. The resolution
for MS1 and MS2 scans were 120 K and 50 K, respect-
ively. Peptides were fragmented using the HCD method
with collision energy fixed at 32%. The precursor isola-
tion window is 1.5 Da.
Proteome Discoverer 2.4 was used for database search
and TMT quantitation. Ratios of raw abundance values
of each sample over the pooled sample were generated
and analyzed in R using the limma package (version 4.0,
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empirical Bayes method) [19]. Briefly, the proteomics
datasets from four MS runs (or two for the lung sam-
ples) were combined and only hits that were detected in
at least 4 out of 6 mice were kept, while the missing 1–2
values were imputed. These phospho-peptide and total
protein datasets were merged and matched for accession
number and the ratio of phospho/total abundance was
generated for phosphopeptide significant hit detection.
Principal component analysis was conducted for these
datasets which revealed a modest batch effect that was
corrected computationally. Statistical analyses were con-
ducted, namely moderated t-tests between pairs were vi-
sualized as volcano plots [20], and z scores were
calculated for heatmaps. Heatmaps were curated from
statistically significant hits selected based on relevance
to neurodegeneration and reported functions on cellular
pathways affected in Parkinson’s Disease. Proteins were
considered significant hits with an adjusted p-value <
0.05, and for kidneys a fold change > 1.4. Functional en-
richment analysis of the significant hits was performed
using the R package gProfiler2 (precision cutoffs of ad-
justed p-values were < 1e-6 and < 1e-20 for kidney and
brain hits, respectively, and term size < 1000 was kept
[21]. All hits from the lungs did not return any signifi-
cant terms within these parameters. Enrichment term
networks were visualized using Cytoscape 3.7 [22].
Additionally, we generated a human interactome of
LRRK2 and compared it with the significant hits found
in kidney total and phospho- proteomics (Fig. S7) using
the PINOT searching tool (http://www.reading.ac.uk/
bioinf/PINOT/PINOT_form.html) which collates pub-
lished, experimentally validated protein-protein inter-
action (PPI) data from 7 different databases (bhf-ucl,
BioGRID, InnateDB, IntAct, MBInfo, MINT and Uni-
Prot), merged the annotations and performed quality
control providing a final score indicative of reproducibil-
ity [23]. The PPIs of LRRK2 with a final score > 2 were
kept as first layer interactors (i.e. reported in literature
as able to directly bind to LRRK2). The first layer inter-
actors of LRRK2 (220 proteins) were used as input in
PINOT to download PPIs able to bind directly to the
first layer (i.e. second layer interactors). The second layer
interactors are proteins that are able to connect to
LRRK2 via their direct connection with a protein within
the first layer (Data File S2). Scripts were run in R (3.6.2)
and networks were drawn using Cytoscape 3.5, mouse to
human protein ID conversion was performed using g:
Profiler [21].
Results
Relative sensitivity of LRRK2 autophosphorylation and
Rab GTPase phosphorylation to MLi-2 inhibition in vivo
Our aim in this series of studies was to mimic a likely
clinical scenario where mutant LRRK2 is inhibited to
levels similar to that seen with wild type protein, thus
nullifying the potential toxic effects of enhanced patho-
genic kinase activity. In order to be able to model this
situation, we first needed to identify reliable markers of
LRRK2 activity in vivo and understand the relationship
between peripheral organ and brain target engagement.
To this end, we compared the response of phosphoryl-
ation of LRRK2 itself and downstream Rab substrates to
MLi-2 in vivo using two acute treatment paradigms.
First, we investigated the dose responsiveness of
LRRK2 autophosphorylation and phosphorylation of Rab
GTPases to acute kinase inhibition in vivo. G2019S KI
mice were given an acute dose of MLi-2 at 1, 3, 10, 30,
60, or 90 mg/kg or vehicle via oral gavage and sacrificed
1 h post dose. We observed significant pS1292 dephos-
phorylation starting at the lowest dose of 1 mg/kg in kid-
ney and lung (Fig. 1a, b). Maximal dephosphorylation
was achieved in the brain, kidney and lung at 10 mg/kg
for both pS1292 and pS935 (Fig. 1a, b, c). Maximal
S1292 dephosphorylation in the brain did not exceed
60% signal decrease with increasing MLi-2 concentra-
tions, suggesting that maximal inhibition was achieved.
The S935 phospho-site had lower IC50 compared to
pS1292 in the brain, suggesting that this marker is more
sensitive to LRRK2 inhibition in vivo.
Phosphorylated Rab GTPases showed more variable
responses to MLi-2 across tissues. The T73 Rab10
phospho-site responded significantly to MLi-2 treatment
in peripheral tissues but not in the brain (Fig. 1a, d).
Phospho- S106 Rab12 showed a robust response to MLi-
2 in both brain and peripheral tissues with maximal de-
phosphorylation at 30-60 mg/kg (Fig. 1a, e; antibody val-
idation experiments are shown in Figs. S2 and S3). The
T71 Rab29 phospho-site responded with treatment in all
tissues but with higher variability compared to Rab12,
especially at lower doses (Fig. 1a, f). At 10 mg/kg, we
saw ~ 50% decrease in Rab10, Rab12 and Rab29 phos-
phorylation in the periphery while higher doses retained
~ 30% residual phosphorylation signal. These results
demonstrate that 10 mg/kg of MLi-2 is adequate to
acutely inhibit LRRK2 autophosphorylation in brain and
peripheral tissues. Based on these results, we selected a
dose of 10 mg/kg MLi-2 for subsequent time course ana-
lyses and washout experiments.
Time course of acute MLi-2 administration reveals that
phosphorylation of Rab GTPases recovers faster than
LRRK2 phosphorylation
To further discriminate how LRRK2 and Rab phosphor-
ylation events vary between brain and peripheral tissues,
we compared time courses and recovery after washout
of inhibitor application. An acute dose of MLi-2 at 10
mg/kg was administered via oral gavage to G2019S KI
mice and sacrificed at 0.5, 1, 3, 12, 24, or 72 h post dose.
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A time point of 0 h was included where animals were
given an equivalent dose of vehicle and euthanized im-
mediately thereafter to measure baseline
phosphorylation.
Phospho- S1292 and S935 LRRK2 showed rapid de-
phosphorylation at 0.5 h, with maximal dephosphoryla-
tion achieved at 1 h post dose across all tissues (Fig. 2a -
c). The dephosphorylation patterns of both phospho-
sites tightly correlated between brain, kidney, and lung
tissues. Interestingly, maximal dephosphorylation for all
pRabs was seen at 1 h in all tissues. However, these sites
recovered more rapidly than pLRRK2 (~ 12 h versus 24
h; Fig. 2a, d - f). Measures of T73 Rab10 signal in brain
tissue did not show MLi-2-dependent dephosphorylation
compared to peripheral tissues (Fig. 2a, d). Dephosphor-
ylation of T71 Rab29 was achieved in all three tissues to
varying degrees, with kidneys showing the strongest re-
sponse to MLi-2, reaching ~ 75% dephosphorylation
compared to 20–30% seen in brain and lung tissue (Fig.
2a, f). pS106 Rab12 mimicked pLRRK2 most closely in
that all tissues showed similar dephosphorylation pat-
terns over time and reached a maximum of 60% dephos-
phorylation (Fig. 2a, e). It was also noted that Rab12
phosphorylation showed the least variability across mice
compared to Rab10 and Rab29. These data suggest that
Rab GTPases are dephosphorylated within the first hour
after LRRK2 inhibition in a similar fashion to LRRK2 de-
phosphorylation, with Rab12 performing similarly to
pLRRK2 in the brain and periphery. In contrast, the kin-
etics of Rab GTPase re-phosphorylation show a quicker
recovery (~ 12 h) compared to LRRK2 (~ 24 h).
In-diet MLi-2 administration can diminish G2019S-
dependent hyperphosphorylation to wild type levels
To evaluate the molecular effects of chronic LRRK2 in-
hibition, we first conducted a dose response experiment
of MLi-2 in diet. With clinical relevance in mind, our
aim was not to fully inactivate LRRK2, as inferred from
Fig. 1 Dose response of acute MLi-2 across brain and peripheral tissues. G2019S LRRK2 knock-in mice were given a single MLi-2 dose via oral
gavage and sacrificed 1 h later. Brain, kidney, and lung homogenates were analyzed by western blot (N = 4 per group; 60 μg of protein were
loaded per well). a, b, c Maximal LRRK2 inhibition was achieved at 10 mg/kg MLi-2 and plateaued with increasing MLi-2 amounts as seen in
S1292 and S935 phosphorylation readouts across all tissues. d pT73 Rab10 showed variability in brain but significant dephosphorylation in
peripheral tissues with treatment. e pS106 Rab12 showed a robust dose-dependent dephosphorylation across all tissues. f pT71 Rab29 showed
variability but a trend of decrease across all tissues with treatment that reached maximal inhibition at the 30-60 mg/kg points. All dose response
curves of the phospho-sites are shown in b-f and represent percentage over vehicle controls of phospho-levels normalized to total protein levels.
IC50 values of Rab GTPases are generally higher and more variable across tissues compared to LRRK2 phosphorylation (IC50s were not reported
when 50% reduction was not reached within the dose-response tested)
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a complete dephosphorylation of S1292, but to amelior-
ate the hyperphosphorylation to a range observed in
wildtype animals.
G2019S KI mice were fed a customized rodent chow
supplemented with MLi-2 to achieve 10, 30, or 60 mg/
kg/day dosing. For reference, we included wildtype and
G2019S KI mice that were fed control chow for 10 days.
In the treated animals, we observed that 60 mg/kg/day
diminished S1292 phosphorylation to wildtype levels in
brain and kidney, whereas a 10 mg/kg/day dose was suf-
ficient to decrease phosphorylation to wildtype levels in
lung tissue (Fig. 3a, b). This suggests some peripheral
tissues with enrichment of LRRK2 may be more sensitive
to drug-induced inhibition. Increasing doses of MLi-2
show a dose response in pS935 LRRK2 (Fig. 3a, c). These
results confirm a dose of 60 mg/kg/day is sufficient to
inhibit G2019S LRRK2 to wild type levels in vivo across
tissues.
Chronic MLi-2 treatment in G2019S KI mice results in
sustained LRRK2 and Rab12 dephosphorylation
To extend these results into a chronic timescale, G2019S
KI mice were given customized chow supplemented with
MLi-2 to reach a 60mg/kg/day dose for 10 days or 10
weeks. Control groups of wildtype, G2019S KI, and
LRRK2 KO mice receiving untreated chow were in-
cluded for reference of baseline phosphorylation pat-
terns. For the purpose of this experiment, we refer to
the 10-day cohort as ‘short-term’ and the 10-week co-
hort as ‘long-term’ treatment groups. The schematic in
Fig. 4a depicts the design of this experiment, in which
brain, kidney, and lung tissues were collected and proc-
essed for Western blot analyses and additionally prepped
for total and phospho-proteomics. Body weight and esti-
mated food intake for each mouse was recorded daily to
determine the daily dose of MLi-2 each mouse received
(Fig. 4b - g). Both short- and long-term cohorts received
Fig. 2 Time-course of target inhibition and rephosphorylation of LRRK2 and Rab GTPase substrates across brain and peripheral tissues. G2019S
LRRK2 knock-in mice were given a single 10mg/kg MLi-2 dose via oral gavage and sacrificed at various time points. Brain, kidney, and lung
homogenates were analyzed by western blot (n = 4 per group; 60 μg of protein were loaded per well) a. Maximal LRRK2 inhibition was achieved
at 1 h post dose as shown by S1292 and S935 dephosphorylation while complete rephosphorylation was achieved by 24 h b, c. Rab10 was
dephosphorylated by 1 h post-dosing in kidney and lung but not in the brain that showed variability in phosphorylated levels and did not
respond to treatment a, d. Rab12 showed robust dephosphorylation by 1 h in brain and periphery a, e. Rab29 responded with maximal
dephosphorylation in brain and lung by 1 h while kidney showed a slower but more significant response a, f. All three Rab GTPases recovered
their phosphorylation levels by 12 h post-dose. These results demonstrate that Rab GTpases are dephosphorylated within the first hour following
LRRK2 inhibition and rephosphorylate quicker than LRRK2 autophosphorylation recovery following wash-out conditions (~ 12 h vs ~ 24 h)
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the appropriate dose of MLi-2 and had comparable
chow intake of ~ 4 g, while weight increase was observed
only in the 10-week cohort, particularly in the LRRK2
KO animals.
In both short-term and long-term cohorts, pS1292
levels of G2019S KI mice treated with MLi-2 were sig-
nificantly decreased to levels comparable to wildtype
mice (Fig. 5a - c). In the long-term cohort, mice treated
with MLi-2 showed further dephosphorylation compared
to wildtype levels in lung (Fig. 5c). S106 Rab12 showed
significant dephosphorylation consistent throughout tis-
sues, similar to the response of LRRK2 dephosphoryla-
tion (Fig. 5a, h - i), proving pRab12 is a reliable readout
of LRRK2 activity and inhibition in this model. Add-
itionally, phosphorylation of S935 LRRK2 was signifi-
cantly reduced in all tissues compared to both G2019S
and wildtype untreated animals in both cohorts as ex-
pected (Fig. 5a, d - e). In contrast, and similar to the tis-
sue and dose-specific responses to acute inhibition,
Rab10 and Rab29 did not respond consistently to LRRK2
inhibition in either 10-day or 10-week groups (Fig. S4 A-
F). To test for covariates of Rab10 phosphorylation, we
ran Pearson’s correlation coefficient on all dosing
experiments in this study, testing for batch of tissue pro-
cessing, gender, dose, age, treatment, and timepoints and
found no contributing factor for the variation in phos-
phorylation (Fig. S4G). Furthermore, total LRRK2 levels
in the 10-day MLi-2 cohort were comparable to their
untreated G2019S counterparts in all tissues, whereas in
the 10-week groups, there was a significant decrease in
LRRK2 levels in kidney with treatment (Fig. 5a, f - g).
This suggests chronic inactivation of LRRK2 leads to ac-
celerated protein degradation, consistent with previous
in vivo and in vitro studies using MLi-2 and other
LRRK2 inhibitors [13, 24].
Unbiased proteomics reveal both therapeutic and
dysregulatory effects in endolysosomal, trafficking, and
mitochondrial pathways with chronic LRRK2 inhibition in
mice
The above studies identified a chronic dosing regimen in
which amelioration of the hyperphosphorylation of the
S1292 autophosphorylation LRRK2 site and pS106
Rab12 in G2019S KI mice can be achieved to levels seen
with wildtype LRRK2 at the endogenous level in vivo.
We next used a series of proteomics approaches to
Fig. 3 Assessment of MLi-2 in-diet dosing and LRRK2 inhibition. G2019S LRRK2 knock-in mice were fed chow containing different concentrations
of MLi-2 to reach 10, 30, or 60 mg/kg/day dosing compared to G2019S knock-in and WT LRRK2 cohorts that were fed control chow. After 10-
days, animals were sacrificed 2–3 h post start of their light cycle. Western blots of brain, kidney and lung tissue samples are shown. a, b Across all
tissues, a significant increase in S1292 phosphorylation is seen in G2019S mice compared to WT animals which is ameliorated with increasing
MLi-2 doses reaching WT levels at 60 mg/kg/day. c A dose-response was seen in S935 dephosphorylation that plateaued at 30 mg/kg/day.
Quantitation of phosphorylation levels is calculated as S1292 and S935 levels over total LRRK2 (b and c: one-way ANOVA with Tukey’s post hoc,
****P < 0.0001, ***P < 0.0002, **P < 0.0021, *P < 0.0332; n = 3; SD bars shown; b F (14, 30) = 52.27, c F (14, 30) = 56.58)
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determine, in an unbiased manner, what the conse-
quences of this treatment might be to tissue proteome.
Proteomic analysis revealed 115 total proteins and 34
phospho-proteins that were differentially expressed in
the kidney between chronic MLi-2-treated and untreated
G2019S LRRK2 mice (false-discovery rate (FDR) ad-
justed p < 0.05; fold change (FC) > 1.4); (Fig. 6a, b).
Among the top differentially abundant proteins, there
was a strong enrichment for endolysosomal, trafficking
and mitochondrial proteins (Fig. 6a, b). Multiple lyso-
somal proteins showed differential abundance, including
cathepsin B (Ctsb), legumain (Lgmn), galactosidase beta
1 (Glb1), Lysosomal-associated membrane protein 1
(Lamp1), and N-acetylglucosamine-6-sulfatase (Gns). In
addition, a number of proteins involved in vesicular traf-
ficking, lipid metabolism, iron uptake and mitochondrial
function were also significantly altered in kidneys of
chronically treated animals. Hierarchical clustering of
differential proteins in the G2019S MLi-2 treated group
showed most similarity to the LRRK2 KO animals (Fig.
6c), suggesting that chronic inhibition of LRRK2 may
mimic features of an absence of LRRK2 in the periphery.
Among the significant phosphoprotein hits, additional
trafficking and mitochondrial proteins were identified,
including sorting nexin 1 (pS188 Snx1) and vacuolar
sorting protein 4b (pS102 Vps4b) (Fig. 6d). Analysis
using Gene Ontology databases of significant hits from
total and phospho-proteins showed enrichment of the
endolysosomal system as well as mitochondrial mem-
brane (Fig. 6e, f).
Additionally, we analyzed the human homologs of
total and phospho-protein hits in silico to identify a
LRRK2 protein-protein interactome using PINOT [23].
We converted the 115 total proteins and 34 phospho-
proteins that were differentially expressed in the kidney
between chronic MLi-2-treated and untreated G2019S
LRRK2 mice to their human orthologues and identified
76 matches within the LRRK2 interactome. Five of the
matching proteins (AHCYL1, EEF2, HSP90AA1,
HSP90AB1 and RANBP2) were present in the first layer
while 71 in the second layer of LRRK2 interactions. The
difference between the average random result from 100,
000 simulated experiments (40 matches) and the real re-
sult (76 matches) was highly significant (p = 2.78*10− 11).
The matching proteins were extracted from the LRRK2
interactome and their connectivity with LRRK2
Fig. 4 Experimental design and dosing paradigm of the chronic in vivo MLi-2 proteomics experiment. a Schematic of experimental design for
the chronic MLi-2 proteomics experiment. b 10-Day cohort animals observed no weight changes (male and female body weight trends are
shown separated within genotypes as square and circle points, respectively) and consumed ~ 4 g of chow per day c. Daily dose of MLi-2 was
calculated by body weight and food intake and showed that animals on average received ~ 65 mg/kg/day of drug d. e 10-Week cohort animals
grew 3-8 g in body weight over the course of 10 weeks (shown as % weight change), with an average food intake of 4 g f and hit the 60mg/kg/
day mark each week g
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visualized (Fig. S7). This high degree of connectivity sug-
gests that these proteins are in fact related to LRRK2
biology rather than an effect of MLi-2 treatment itself.
Proteomic analysis of brain tissue of 10-week MLi-2-
treated mice revealed a number of mitochondrial pro-
teins that showed statistically significant p-value (ad-
justed p < 0.05) compared to untreated G2019S KI
controls, albeit with modest fold differences between
treatment groups (Fig. 7a, b). These include Cytochrome
C, NADH:Ubiquinone Oxidoreductase Subunit V3
(Nduvf3), the mitochondrial ATP synthase Atp5g1 and
Voltage Dependent Anion Channel 2 (Vdac2) (Fig. 7a,
b). Phospho-proteomics analysis revealed a decrease in
S58 phosphorylation of the ion transporter Fxyd7 and
increase in S109 phosphorylation of the PP2A inhibitor
Ensa (Fig. 7b). Gene Ontology analyses revealed enrich-
ment for proteins residing in different mitochondrial
compartments as well synaptic proteins (Fig. 7c, d).
These data suggest that even though the brain is more
resilient in terms of potential endolysosomal defects that
may be associated with LRRK2 inhibition, there are
small changes in mitochondrial function resulting from
chronic LRRK2 inhibition. Volcano plots comparing un-
treated groups of G2019S KI and wildtype mice showed
that a number of proteins had the opposite trend to that
seen in the chronic MLi-2 cohort (Fig. S5). For example,
the transmembrane ion transporters Sfxn2 and Sfxn3,
showed a modest upregulation in kidneys of G2019S
LRRK2 compared to wildtype mice and this was rescued
in the chronic MLi-2 G2019S LRRK2 cohort (Figs. S5A
and Fig. 6a). For some mitochondrial proteins identified
in our brain proteomics screen, Cytochrome C, Vdac1,
Ndufs3, and Ndufv2 were downregulated in G2019S
LRRK2 brain compared to wildtype and this was re-
versed in the chronic MLi-2 G2019S LRRK2 cohort
(Figs. S5B and 7A). This suggests that treatment can sig-
nificantly alter the expression of mitochondrial proteins
in G2019S KI mice in a direction consistent with thera-
peutic potential.
Finally, 441 total proteins and 189 phosphopeptides
were identified in whole lung homogenates as significant
with an adjusted p-value of < 0.05, of which 14 phospho-
peptides and 6 total proteins passed the fold change cut-
off of 1.4x in the G2019S MLi-2 treated versus untreated
mice (Fig. 7e-f). Of the significant proteins identified, we
attempted to validated Myristoylated alanine-rich C-
kinase substrate.
(Marcks) due to potential relevance to known LRRK2
pathways. Phosphorylation of Marcks within its ED do-
main localizes the protein to the plasma membrane of
cells, as unphosphorylated protein is released into the
cytosol and can bind GTP-bound Rab10 [25], a LRRK2
substrate. Marcks may also be relevant to lung inflam-
mation [26, 27], where LRRK2 has also been implicated
[28]. Marcks phosphorylated at S163 was significantly
decreased in the MLi-2 treated group and was validated
via Western blot (Fig. S6C-D). Additionally, Cyp1a1, a
monooxygenase widely distributed via the bloodstream
responsible for metabolizing various classes of drugs and
carcinogens [29], was upregulated in the lungs of
G2019S KI mice treated with MLi-2, which we also vali-
dated (Fig. S6C-D). Although these results confirm valid-
ity of the lung proteomics results, we did not recover
any significant Gene Ontology categories, presumably
due to the relative sparsity of significant changes in the
lung proteome.
Validation of endolysosomal, trafficking, and
mitochondrial proteins in chronically LRRK2 inhibited
mice reveal both a rescue of mutant-driven effects and
dysregulatory patterns in vivo
We next wanted to validate protein hits observed from
our proteomics screens in kidney tissue. Through west-
ern blot analyses, we found two distinct patterns of ef-
fects, one we characterized as beneficial, based on a
reverse in protein expression from G2019S KI animal
levels back to wildtype levels and the other dysregula-
tory, based on a mimicking effect comparable to LRRK2
KO animals (Fig. 8a). In the former category, the non-
glycosylated form of Lamp1, the ESCRT-0 protein Hgs,
and the iron and serine mitochondrial transporter Sfxn3
were all shown to be significantly increased in protein
levels in untreated G2019S KI mice compared to wild-
type animals. These levels were ameliorated back to
wildtype levels after MLi-2 treatment for 10 weeks (Fig.
8b). Conversely, the glycosylated form of Lamp1 and the
lysosomal hydrolase Legumain were both significantly
increased in the same animals, patterns of which have
been previously characterized in LRRK2 KO animals,
and is recapitulated here in our LRRK2 KO mice in this
(See figure on previous page.)
Fig. 5 LRRK2 and S106 Rab12 phosphorylation following chronic MLi-2 treatment. WT, G2019S LRRK2 KI, and LRRK2 KO mice were fed vehicle or
MLi-2-containing chow over the course of 10 days or 10 weeks a. LRRK2 inhibition is maintained between the short-term (10-day) and long-term
(10-week) chronic treatment as shown by decrease in pS935 levels d, e and S1292 LRRK2 dephosphorylation b, c to levels comparable to WT
controls. A decrease in total LRRK2 levels is observed in peripheral tissues with chronic treatment in by 10 days f and is exacerbated in the 10-
week treatment g. S106 Rab12 phosphorylation levels show a significant decrease with treatment to levels comparable to WT tissue h, i. One-way
ANOVA with Tukey’s post hoc; n = 6; ****P < 0.0001, ***P < 0.0002, **P < 0.005, *P < 0.05; b F (11, 60) = 146.8, c F (11, 60) = 178.7, d F (11, 60) =
158.0, e F (11, 60) = 265.9, f F (11, 60) = 75.97, g F (11, 60) = 271.5, h F = (11, 60) = 65.78, i F (11, 60) = 59.67
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cohort [30]. In addition, we also discovered that the
motor adaptor protein Jip4 was significantly reduced in
LRRK2 KO mice, and this was also seen in G2019S KI
mice treated with MLi-2 (Fig. 8c). Jip4 has recently been
discovered, by our lab and others, to bind to LRRK2-
dependent phosphorylated Rab8a, Rab10, and Rab35 and
can be recruited to damaged lysosomal membranes [31,
32]. In the current study, all of these phenotypes are
kidney-specific, as no significant difference of these pro-
teins was observed in brain or lung tissues (Fig. S6 A-D).
Additionally, these differences were not seen in mice
that were treated with MLi-2 for only 10 days (Fig. S6
G-I), suggesting that chronic inhibition of LRRK2 is ne-
cessary to see these effects.
Discussion
In the present study, we have evaluated various markers
of LRRK2 inhibition in vivo and demonstrated their util-
ity across brain and peripheral tissues. In both acute and
chronic treatment paradigms, we focused on a treatment
paradigm that might reasonably mimic clinical applica-
tions where the hyperactive mutant of LRRK2, G2019S,
expressed at the endogenous level is chronically de-
pressed to that of wildtype animals. We performed pro-
teomics to examine the molecular effects of chronic
LRRK2 inhibition and identified changes to the endoly-
sosomal, trafficking, and mitochondrial systems in kid-
neys at the total protein level as well as phosphorylation
events. In addition, we noted a modest but statistically
significant change in mitochondrial proteins, most not-
ably enriched within the mitochondrial electron trans-
port chain, in the brains of MLi-2 treated G2019S mice.
In our studies in mouse tissue, measuring LRRK2
phosphorylation, particularly the pS1292 autophospho-
rylation site, provides the most reliable marker of both
G2019S-induced hyperactivity and MLi-2 dependent in-
hibition. Whether this can be extrapolated to human
clinical samples is unclear as current tools have not
yet allowed for robust detection of pS1292 LRRK2 in
peripheral blood, although some studies have
demonstrated its efficacy in urinary and CSF exosomes
[33, 34]. Using the commercially available pRab anti-
bodies, we found that S106 Rab12 phosphorylation pat-
tern resembled that of pS1292 LRRK2 most closely
across experiments, in that G2019S KI mice displayed
hyperphosphorylation that was ameliorated with MLi-2
treatment. This is in contrast to the hyperphosphoryla-
tion pattern of other Rab substrates, which have been
demonstrated in mutations within the GTPase domain
but not for G2019S [35, 36]. Thus, for G2019S-carriers
and potentially other PD cases, detection of pRab12 has
potential as a biomarker for LRRK2 activity and
inhibition.
With regard to pRab10 and pRab29, we show that
their levels do not correlate with MLi-2 treatment
in vivo, particularly within the chronic in-diet treatment
paradigm. We hypothesize a few reasons for this. Firstly,
Vieweg et al. reported a PINK1-dependent S111
phospho-site conserved across multiple Rab substrates
that can negatively regulate subsequent LRRK2-
dependent phosphorylation by preventing Switch-II
binding with its GEF, as demonstrated with pT72 Rab8a
in vitro [37]. It is possible that Rab10 and Rab29
LRRK2-dependent phosphorylation could be regulated
through a similar unknown mechanism and thus no
change to basal levels of phosphorylation are observed
with LRRK2 inhibition. Additionally, other unknown ki-
nases that phosphorylate these Rabs on the same residue
as LRRK2 and normally compete with LRRK2 for bind-
ing may be able to phosphorylate these proteins more
readily under conditions of LRRK2 inhibition. Lastly, we
recently reported differing localization patterns between
pS106 Rab12 and pT73 Rab10 when artificially trapping
LRRK2 to different cellular membranes. Independent of
which membrane LRRK2 was directed to intracellularly,
pRab12 was found to colocalize with LRRK2, whereas
pRab10 was primarily detected at perinuclear lysosomes
and Golgi after directing LRRK2 to these membranes
[38]. This falls in line with the idea that a more complex
mechanism surrounds the Rab10:LRRK2 interaction and
(See figure on previous page.)
Fig. 6 Proteomic analysis of changes in kidney between G2019S LRRK2 MLi-2 and G2019S vehicle 10-week treated mouse cohorts. a
Volcano plot showing changes in protein levels following chronic treatment, depicted as log2 fold changes (x-axis) versus the −log10 of adjusted
p-values (y-axis) for each protein. A number of endolysosomal proteins were upregulated, including legumain and other lysosomal proteases in
kidneys of G2019S LRRK2 KI mice that received chronic MLi-2 treatment for 10 weeks, compared to vehicle G2019S KI controls. b Heat maps of
selected significant hits across the WT, G2019S KI and LRRK2 KO vehicle cohorts as well as the G2019S KI chronic MLi-2 cohort, highlighting
proteins involved in vesicular trafficking, lipid metabolism, transferrin recycling and mitochondrial homeostasis. Z score is used for scaling. Using
unsupervised hierarchical clustering we show that the G2019S MLi-2 and LRRK2 KO mice cluster together, suggesting that chronic LRRK2
inhibition mimics a LRRK2 KO effect in kidney. c Bubble plot showing GO:CC term enrichment in the significant total protein hits highlights
enrichment for endolysosomal processes and compartments. d Volcano plot showing changes in phospho-proteins in G2019S MLi-2 treated vs
G2019S untreated mice, highlighting dysregulation of proteins involved in trafficking, glucose transport and metabolism, and the TCA cycle e. f
Bubble plot showing GO:CC term enrichment in the significant phospho-peptide hits highlights enrichment for endolysosomal processes as well
as kidney-specific functional processes. Volcano plots key: grey = non-significant, blue = < 0.05 p-value, green = > 1.4x log fold change, red = <
0.05 p-value and > 1.4x log fold change
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Fig. 7 Proteomic analysis of changes in brain and lung between G2019S LRRK2 MLi-2 and G2019S vehicle 10-week treated mouse cohorts. A
volcano plot from total proteomics of whole brain tissue comparing the G2019S chronic MLi-2 cohort versus G2019S KI vehicle controls a.
Modest upregulation was observed in mitochondrial proteins with treatment, specifically proteins of the electron transport chain a. Heatmap
visualizes changes in phosphopeptides with treatment highlighted proteins involved in vesicular trafficking and postsynaptic regulation on a z
score scale b. GO:CC term enrichment bubble plots were generated from the significant hits of the total and phospho-proteomics showing high
enrichment for mitochondrial compartments, as well as proteins associated with postsynaptic function, respectively c-d. Volcano plots from total
and phospho-proteomics of whole lung homogenates comparing treated versus untreated G2019S KI mice e-f. Volcano plots key: grey = non-
significant, blue = < 0.05 p-value, green = > 1.4x log fold change, red = < 0.05 p-value and > 1.4x log fold change
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thus any influence LRRK2 has on Rab10 is more condi-
tional compared to Rab12. These hypotheses could ex-
plain the lack of dephosphorylation of T73 Rab10 in the
presence of MLi-2, and further exploration of other ki-
nases and phosphatases that regulate Rab GTPase phos-
phorylation, such as PPM1H [39], will be necessary to
elucidate the functional dynamics between Rab10 and
LRRK2 across different organelles.
Using these two validated biomarkers, pS1292 LRRK2
and pS106 Rab12, a 60 mg/kg/day dosing of MLi-2 in
G2019S KI mice via in-diet dosing for 10 days or 10
weeks was shown to be sufficient to revert the hyper-
active mutation approximately to wild type levels. Such
an approach could be helpful in identifying similar dos-
ing regimens in humans. Importantly, we show that
measurements in some peripheral tissues, particularly
kidney, reflect events in the brain, the target organ for
any PD clinical trial. However, we observed that after
long-term chronic MLi-2 in-diet dosing, S1292 LRRK2
and S106 Rab12 phosphorylation was significantly lower
than wildtype levels in lung. It is possible that lung tissue
is more sensitive to LRRK2 inhibition than other tissues
considered here and has also been suggested in a recent
study investigating the toxicological and morphological
effects of LRRK2 inhibition on nonhuman primate lungs,
in which high doses of three structurally distinct
LRRK2-specific inhibitors, including MLi-2, induced vac-
uolated cytoplasm in type II pneumocytes, however no
pulmonary deficits were observed and the phenotype
was quickly reversed after cessation of treatment [16].
These data were recently recapitulated in mice by Bryce
and colleagues. In this study the authors treated wildtype
mice with in-diet MLi-2 for six months and showed that
the levels of prosurfactant protein C were increased early
on in a 60 mg/kg/day dosing regimen and decreased
back to control levels after 90 days [40]. These reports
suggest that there is a lung-specific LRRK2-dependent
mechanism that is affected by chronic LRRK2 inhibition.
Based on these data, we probed our 10-day and 10-week
treatment cohorts for proSP-C in lung tissue via West-
ern blot. We found no changes at either timepoints in
G2019S KI mice treated with MLi-2, although a slight
but significant elevation of proSP-C was observed in the
Lrrk2 KO animals (Fig. S6C-F). This would imply that
the absence of LRRK2 has an effect of proSP-C levels
and MLi-2 treatment would have a more dramatic effect
on wildtype mouse lung tissue than in a G2019S KI. A
60mg/kg-dosing inhibition on wildtype activity could
potentially mimic LRRK2 deficiency and this is not reca-
pitulated in our regimen where we aimed to lower
G2019S LRRK2 activity to wildtype levels. Another im-
portant aspect to note is the potential limitation in de-
tecting surfactant changes by western blot, due to their
~ 90% lipid/10% composition and further lipid analysis
would be more informative in comparing wildtype and
G2019S hyperactive kinase inhibition for possible differ-
ences. Overall, these data suggest that while LRRK2 in-
hibitors can be used to diminish hyperactive kinase to
wild type levels of activity, there are tissue-specific dif-
ferences in activity and stability of the protein that may
be important to consider when using peripheral engage-
ment to infer brain inhibition.
Unbiased proteomic screens revealed significant differ-
ences in endolysosomal, trafficking, and mitochondrial
proteins in the kidneys of treated compared to untreated
G2019S KI animals. We identified two subsets of pro-
teins, those that suggest a therapeutic effect and those
that are dysregulatory, with long-term chronic LRRK2
inhibition in vivo. Strikingly, all differential changes were
specific to our 10-week treatment cohort compared to
our 10-day cohort. This suggests that these molecular
changes are specific to the length of LRRK2 inhibition.
Thus, future preclinical efforts are needed that include
long-term inhibitor treatment in order to understand
what may happen in human disease. Proteins altered to-
wards a therapeutic effect included non-glycosylated
Lamp1, Hgs, and Sfxn3, whereas glycosylated Lamp1,
leguman, and Jip4 showed likeness to LRRK2 KO ex-
pression levels. Based off of these proteins, we
hypothesize a mechanism for the endolysosomal traffick-
ing pathway in the context of both LRRK2 kinase hyper-
activity and chronic inhibition, in which both
dysfunctional LRRK2 kinase states converge on the same
pathway through different means depicted in Fig. 8d.
(See figure on previous page.)
Fig. 8 Validation of proteomic hits reveal both rescue of mutant-driven effects and dysregulatory patterns in long-term MLi-2 treated mice.
Follow-up validation of proteomics hits in Western blot confirmed differential changes to endolysosomal, trafficking, and mitochondrial proteins.
Within these proteins, we observed divergent patterns of therapeutic and dysregulatory effects in the kidneys of 10-week, MLi-2 treated G2019S
KI mice a. Therapeutic trends were observed in non-glycosylated Lamp1, Hgs, and Sfxn3, in which high expression of these proteins in untreated
G2019S KI mice were ameliorated down to wildtype levels with LRRK2 inhibition b. We also observed significant increases in glycosylated Lamp1
and Legumain towards levels observed and previously characterized in Lrrk2 KO mice. Additionally, we have shown a significant decrease in Jip4
within the treated mice that were also exacerbated in Lrrk2 KO mice c. Based on these discoveries, we have hypothesized divergent mechanisms
for LRRK2 hyperactivity and chronic inhibition d. The proteins in maroon reflect the proteins identified in our proteomics screens (italicized) and
validation on WB (not italicized). The grey dashed arrows depict unknown mechanism/relationship with LRRK2 kinase activity. One-way ANOVA
with Tukey’s post hoc; n = 6; ****P < 0.0001, **P < 0.005, *P < 0.05; b non-glycosylated Lamp1: F (3, 19)= 13.58, Hgs: F (3, 19)= 13.72, Sfxn3: F (3,
19)= 9.323, c glycosylated Lamp1: F (3, 19)= 13.70, Legumain: F (3, 20)= 61.36, Jip4: F (3, 20)= 27.39
Kluss et al. Molecular Neurodegeneration           (2021) 16:17 Page 15 of 19
In recent years, the role of LRRK2 at the lysosome
has been a focus of research that explores how muta-
tions in this gene cause disease. Multiple labs have
now reported lysosomal dysfunction in both LRRK2
KO and G2019S mutant models, LRRK2 recruitment
to lysosomes under stress as well as alpha-synuclein
accumulation in Lrrk2 deficient models [10, 17, 32,
41]. We show here that increased non-glycosylated
Lamp1 found in G2019S KI mice was ameliorated
back to wildtype levels after 10-week MLi-2 treat-
ment. Glycosylation of Lamp1 is an important feature
in maintaining lysosomal stability and protein trans-
port across its membrane [42]. Glycosylation is initi-
ated in the rough endoplasmic reticulum and moves
through the Golgi before reaching lysosomes. Thus,
an increase in the non-glycosylated form suggests ei-
ther that there has been an incomplete maturation of
Lamp1 before reaching the lysosomes or an upregula-
tion in Lamp1 translation due to increased lysophagy
in the kidneys of G2019S KI mice. Premature lyso-
phagy and redirection of proteins for degradation to
the remaining active lysosomes may then overwhelm
the system and lead to lysosomal stress. In contrast,
an increase in glycosylated Lamp1 has been previously
characterized in Lrrk2 KO mice and in the postmor-
tem brains of sporadic PD patients [30, 43] and is
shown here in G2019S KI mice treated with MLi-2
and LRRK2 KO mice. This suggests that there can be
lysosomal buildup and protein accumulation in the
absence of active LRRK2. Both alterations of Lamp1
suggest LRRK2 kinase activity plays a role in the in-
tegrity of lysosomes, and chronic inhibition of LRRK2
may restore healthy levels of the non-glycosylated
form, while perpetuating a shift that mimics a loss of
function effect in its glycosylated form. This suggests
that treatment with LRRK2 kinase inhibitors may re-
quire careful consideration of both premature lyso-
phagy and lysosomal protein accumulation.
In brain tissue, chronic MLi-2 treatment in G2019S
KI mice showed a modest but significant upregulation
of mitochondrial proteins compared to their untreated
counterparts (Fig. 7a). Production of reactive oxygen
species (ROS), mitochondrial elongation, decreased
ATP production and mitochondrial DNA damage
have been reported in G2019S PD patient-derived
skin biopsies and G2019S-LRRK2 in vitro models
[44–48]. In brain tissue, the majority of mitochondrial
proteins found in our screens were associated with
the respiratory chain Complex I and III. Further stud-
ies are needed in order to elucidate the effects of
LRRK2 on the respiratory chain system. However,
these results do not suggest a potential concern for
LRRK2 kinase inhibition affecting mitochondrial func-
tion as in general they respond in the opposite
direction of effect to the pathogenic G2019S muta-
tion, i.e. are in the therapeutic direction. A limitation
of this study is that whole brain homogenate was
used for the proteomics analysis which may have lim-
ited our ability to determine regional- and cell type-
dependent LRRK2 mechanisms. Further studies fo-
cused on regional and cell-specific parameters can
shed a deeper mechanistic insight into the molecular
consequences of LRRK2 inhibition in the brain.
Conclusion
The aim of the present study was twofold: to assess the
suitability of new antibodies of known LRRK2 substrates
as biomarkers for LRRK2 kinase inhibition and to evalu-
ate what molecular effects are observed when LRRK2 is
chronically inhibited. We found that pRab12 is a reliable
readout of LRRK2 activity and inhibition, and that phos-
phorylation patterns seen in the periphery reflect events
in the brain. Additionally, our study highlights the mo-
lecular effects of chronic inhibition that remain to be ex-
plored and warrant further investigation in the light of
the ongoing clinical trials. What remains to be deter-
mined is which of these effects are truly protective or
damaging, and how relevant they are to what happens in
human disease.
As of yet, there continues to be a significant unmet
medical need in the field of neurodegeneration for ef-
fective, long lasting treatments that either halt or slow
disease progression. Existing drug treatments for PD
target the symptoms of the disease rather than cause,
and do not modify disease course. Clinical trials are
currently underway to assess the safety and efficacy of
LRRK2-specific kinase inhibition in PD patients [49].
In parallel with these trials, future work will need to
elucidate the underlying disease mechanisms that
cause PD and how LRRK2 mutations ultimately lead
to neurodegeneration. Understanding the pathobiolo-
gical role of LRRK2 kinase activity will greatly aid in
the development and optimization of therapeutic
strategies.
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Additional file 1 Table S1: Table of antibody summary. All antibodies
used in this study are listed with catalog numbers, and working
concentrations used. IgG concentrations are supplied in brackets.
Additional file 2 S2. Characterization of pT73 Rab10 [MJF-R21 and MJF-
R21–22-5] antibodies. (A, B) HEK293FT cells transiently expressing LRRK2 mu-
tant constructs were analyzed for endogenous Rab10 phosphorylation
[MJF-R21]. The LRRK2 genetic variants R1441G, Y1699C and I2020T invoked
the highest increase in Rab10 phosphorylation compared to WT LRRK2,
while the kinase-dead K1906M LRRK2 construct conferred a significantly
lower pRab10 levels compared to WT. (C, D) HEK293FT cells transiently ex-
pressing LRRK2 genetic variants following Rab10 siRNA knock-down were
probed for Rab10. Rab10 levels revealed successful knock-down of en-
dogenous Rab10 compared to non-targeting controls. The pT73 Rab10
[MJF-R21] antibody detected a band at ~ 24 kDa, which was not detected in
the Rab10 siRNA groups, suggesting specificity for Rab10. (E, F) In a similar
experiment to (C), Rab10 expression was knocked-down in primary astro-
cytes from WT and homozygous G2019S LRRK2 knock-in mice. Rab10
knock-down was followed by a significant decrease in pT73 Rab10 signal
using the MJF-R21 antibody (E, F). (G, H) Primary astrocytes treated with
1 μM of MLi-2 for 90min showed that both pT73 Rab10 antibodies (MJF-
R21 and MJF-R21–22-5) show significantly decreased levels of phosphoryl-
ation compared to control cells. Quantitation of phosphorylation levels in D
and F are presented as raw pT73 intensity normalized to loading while B
and H represent T73 phosphorylation signal over total Rab10 levels (B: one-
way ANOVA with Tukey’s post hoc, ****P < 0.0001, ***P < 0.0002, n = 3, F (8,
18)= 45.45. D: two-way ANOVA with Sidak’s multiple comparisons test;
LRRK2 construct, p < 0.0001, F (2, 12)=30.73; siRNA, p < 0.0001, F (1, 16)=
550.0, n = 3. F: two-way ANOVA with Sidak’s multiple comparisons test;
LRRK2 construct, p = 0.7361, F (1, 8)=0.1218; siRNA, p < 0.0001, F (1, 8)=56.29,
n = 3. H: one-way ANOVA with Tukey’s post hoc, ****P < 0.0001, n = 3; F (3,
15)= 160.3). S3. Characterization of pS106 Rab12 [MJF-25-9] and pT71 Rab29
[MJF-R24–17-1] antibodies. (A) HEK293FT cells transiently expressing LRRK2
genetic variants following siRNA knock-down of Rab12 were analyzed for
Rab12 phosphorylation. The pS106 Rab12 antibody showed a strong band
at ~ 25 kDa with LRRK2 transfection, which was significantly decreased by
Rab12 siRNA compared to non-targeting control (A, B). (C, D) HEK293FT cells
transiently expressing LRRK2 mutant constructs were analyzed for endogen-
ous pT71 Rab29. Endogenous Rab29 was found hyperphosphorylated in
R1441C, R1441G, Y1699C, G2019S and I2020T LRRK2 expressing cells, com-
pared to WT LRRK2. (E, F) siRNA Rab29 knockdown resulted in a significant
decrease in pT71 Rab29 signal in HEK293FT cells over-expressing LRRK2 mu-
tants compared to non-targeting controls. (G) The T71 Rab29 antibody
tested did not detect a band in cells expressing the T71A Rab29 phospho-
null variant while a strong band was observed in cells expressing WT Rab29
construct, in co-expression with LRRK2 constructs. (H) Lung tissue collected
from Rab29 KO mice tissue showed no pT71 Rab29 signal, whereas G2019S
Lrrk2 knock-in mice showed increase in Rab29 phosphorylation, compared
to WT mice. Quantitation of phosphorylation levels is presented as S106 nor-
malized to loading (cyclophilin B levels; in B), T71 over total Rab29 (in D) or
normalized to loading (F). (B: two-way ANOVA with Sidak’s multiple compar-
isons test; LRRK2 construct, p = 0.0083, F (2, 12)=7.329; siRNA, p < 0.0001, F (1,
16)=367.8, n = 3. D: one-way ANOVA with Tukey’s post hoc, ****P < 0.0001,
***P < 0.0002, ** < 0.004, F (8, 18)= 528.0, n = 3. F: two-way ANOVA with
Sidak’s multiple comparisons test; LRRK2 construct, p < 0.0001 F (2, 12)=
31.83; siRNA, p < 0.0001, F (1, 16)=191.1, n = 3. Mean values with SD bars
shown). S4. pT73 Rab10 and pT71 Rab29 phosphorylation following chronic
MLi-2 treatment. Full blots from the 10-day and 10-week chronic studies are
shown to account for animal-to-animal variability (A, B). pT73 Rab10 across
tissues and treatment groups show large variability with no discernable
trend after LRRK2 inhibition (C, E). Rab29 T71 phosphorylation levels do not
respond to treatment across tissues and time points, with exception to brain
tissue of the short-term cohort (D, F). (G) Pearson’s correlation coefficients
were conducted to test confounding variables within the acute and chronic
paradigms of this study with regard to pT73 Rab10 variability, of which rela-
tionships with dose of MLi-2, length of experiment, age of mice, gender,
and batch of tissue processing were not found. One-way ANOVA with
Tukey’s post hoc; n = 6; ****P < 0.0001, ***P < 0.0002, **P < 0.005, *P < 0.05;
(C) F (11, 60) = 28.56, (D) F (11, 60) = 43.20, (E) F (11, 59) = 24.70, (F) F (11,
60) = 8.279. S5. Proteomic analysis of changes in brain, kidney, and lung be-
tween untreated G2019S LRRK2 and wildtype mouse cohorts. Volcano plots
depicting differences in levels of total proteins in kidney (A), brain (B), and
lung (C) between untreated G2019S KI and wildtype mice. A number of pro-
teins show subtle changes involved in iron transport and mitochondrial
homeostasis are highlighted. Lung hits were not preferentially enriched for
any particular cellular component. Volcano plots key: grey = non-significant,
blue = < 0.05 p-value, green = > 1.4x log fold change, red = < 0.05 p-value
and > 1.4x log fold change. S6. Kidney hits are tissue-specific with proteins
identified in the 10-week cohort and do not show differential change in the
10-day cohort. Proteins identified in the kidney proteomics and validated
via Western blot were also investigated in the brain and lung tissues of the
10-week cohort animals. We found that these proteins (Jip4, Lamp1, HGS/
Vps27, Sfxn3 and legumain) were not statistically altered in the G2019S KI
animals, neither MLi-2 treated nor untreated, in brain and lung (A-D). This
implies a kidney-specific phenotype of these altered lysosomal and other
membrane proteins. Additionally, we explored two of the mitochondrial
proteins found in the brain total proteomics, Atp5mc1 and Cytochrome C.
No difference was observed in G2019S MLi-2 treated mice compared to any
other group (C-D). Additionally, proteins Cyp1a1 and pS163 Marcks identi-
fied in the lung proteomics were validated via Western blot analysis (C-D).
Prosurfactant C was measured in both 10-week (C) and 10-day (E) cohorts in
lung tissue of which Lrrk2 KO animals showed a significant elevation while
G2019S KI animals receiving MLi-2 treatment were not affected in either co-
hort (C-F). Proteins identified as statistically significant in the 10-week cohort
were also investigated in the 10-day cohort in order to determine if the ef-
fects observed occur after continued use of LRRK2 inhibitor long-term as
opposed to more immediate effects (after 10 days). Western blot analysis
confirmed that both therapeutic and dysregulatory effects were not ob-
served in the 10-day cohort of treated animals (G-I). This suggests that the
endolysosomal, trafficking, and mitochondrial changes we observed in our
proteomics screen are effects of long-term treatment with MLi-2 in G2019S
KI mice. Interestingly, the increase in protein expression in our untreated
G2019S KI that was observed in our 10-week cohort, specifically non-
glycosylated Lamp1, Hgs, and Sfxn3 was not seen in our 10-day cohort (H).
Our current hypothesis is that these changes in protein expression are age-
dependent in the context of the G2019S mutation in the mouse model, as
the 10-week animals are double the age of the 10-day cohort at time of sac-
rifice. One-way ANOVA with Tukey’s post hoc; n = 6; ****P < 0.0001, ***P <
0.0002, **P < 0.005, *P < 0.05; (B) Jip4: F (3, 20)= 0.8688, glycosylated Lamp1:
F (3, 20)= 0.4520, HGS: F (3, 20)= 0.1410, Legumain: F (3, 20)= 0.2312,
Atp5mc1: F (3, 20)= 1.953, Sfxn3: F (3, 20)= 0.2285, Cytochrome C: F (3, 20)=
1.698, (D) F (3, 20)= Jip4: F (3, 20)= 1.772, HGS: F (3, 20)= 0.1636, Legumain: F
(3, 20)= 0.1724, Sfxn3: F (3, 20)= 1.156, pS163 Marcks: F (3, 20)= 4.739,
Cyp1a1: F (3, 20)= 208.2, ProSP-C: F (3, 20)= 4.495, (F) ProSP-C: F (3, 20)=
4.185, (H) non-glycosylated Lamp1: F (3, 20)= 2.802, Hgs: F (3, 20)= 5.173,
Sfxn3: F (3, 20)= 3.002, (I) glycosylated Lamp1: 4.702, Legumain: F (3, 20)=
4.409, Jip4: F (3, 20)= 12.35. S7. LRRK2 protein interactome from long-term
chronic kidney proteomics. The 149 mouse kidney protein hits from chron-
ically treated G2019S KI mice were converted to their human orthologues
for LRRK2 interactome analyses using PINOT online tool. Seventy-six
matches were identified within the LRRK2 interactome. Five of the matching
proteins (AHCYL1, EEF2, HSP90AA1, HSP90AB1 and RANBP2) were present in
the first layer while 71 in the second layer of LRRK2 interactions (one step
from direct LRRK2 interactors). Two visualizations are shown: (A) highlights
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